8 citations
,
October 2006 in “Current Pharmaceutical Design” Common gene patterns may cause skin autoimmune diseases.
2 citations
,
April 2013 in “PubMed” Abnormal T-cells from thymomas cause non-motor symptoms in some myasthenia gravis patients.
1 citations
,
July 2023 in “Pharmaceutics” New microneedles deliver drugs through the skin accurately and effectively.
1 citations
,
September 2023 in “Journal of Investigative Dermatology” Melatonin may protect hair follicle cells from damage caused by a chemotherapy drug.
6 citations
,
January 2013 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” A new compound shows promise as a topical treatment for hair loss.
January 2026 in “ACS Applied Bio Materials” A new treatment using nanoliposomes can improve hair regrowth in androgenetic alopecia.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
25 citations
,
April 2014 in “Journal of Scientific and Innovative Research” Tridax procumbens may help treat diabetes.
April 2026 in “SSRN Electronic Journal”
6 citations
,
June 2018 in “PLOS ONE” The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.
June 2023 in “Dermatologic Surgery” New injection methods for hair loss treatment show promise but need more research.
6 citations
,
August 2013 in “Joint Bone Spine” Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.
13 citations
,
February 2017 in “Clinical rheumatology” Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
Minoxidil and a solvent mixture can prevent hair loss caused by chemotherapy in mice.
Injecting patients' own PRP into their thyroid improved thyroid function and symptoms in most hypothyroidism cases.
36 citations
,
April 2016 in “British journal of dermatology/British journal of dermatology, Supplement” A substance called VIP might protect hair follicles from being attacked by the immune system, and problems with VIP signaling could lead to hair loss in alopecia areata.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
12 citations
,
December 2022 in “Current Protein and Peptide Science” Thymosin β4 helps in cell activities, healing, and organ preservation, and treats hair loss and skin injuries.
New treatments for alopecia areata, like JAK inhibitors and immunomodulators, are promising.
June 2026 in “Advanced Healthcare Materials” A new taurine-based liquid can help treat hair loss by improving hair follicle health and promoting regrowth.
11 citations
,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
October 2025 in “Journal of Cosmetic Dermatology” Botulinum toxin Type A helps reduce hypertrophic scars and is generally safe.
August 2025 in “Archiv Euromedica” Gut microbiota changes might play a role in alopecia areata, and microbiome-targeted treatments show promise.
May 2024 in “Archives of Dermatological Research” TAT-GILZ peptide promotes hair growth by boosting stem cell activity.
January 2021 in “Research Portal Denmark” Tofacitinib helped a man with alopecia totalis regrow all his hair.
25 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Targeted cytokine treatments may help with alopecia areata, but more research is needed.
April 2025 in “BMC Immunology” Targeting SIRT1 with antisense oligonucleotides could be a promising treatment for hair loss.
September 2011 in “American Journal of Transplantation” Hair regrowth in alopecia universalis may be possible by altering immune cells.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.